NeuroZika Patient Outcomes from French West Indies Outbreak

An observational study of 87 ZIKV-infected patients with neurological manifestations during the 2016 French West Indies outbreak. The data characterizes the spectrum and prognosis of NeuroZika, with clinical follow-up available for 76 patients over a median of 14 months. It includes outcomes such as residual disability rates and mortality.

Use Cases

• Analyze the association between ZIKV RNA detection in biological fluids and the risk of residual disability or death.
• Model the relative frequency and prognosis of different neurological manifestations like Guillain-Barré syndrome and encephalitis.
• Study the clinical outcomes, including mechanical ventilation requirements and disability scores (modified Rankin scale), across patient subgroups.

Strengths

• Data from 87 consecutively enrolled patients provides a defined clinical cohort.
• Includes long-term follow-up data for 76 patients with a median observation period of 14 months.
• Captures a detailed spectrum of neurological manifestations with quantified frequencies (e.g., 46.0% Guillain-Barré syndrome).

Limitations

• Small sample size of 87 patients limits statistical power for rare outcomes.
• Geographic focus on the French West Indies may limit generalizability to other populations.
• Observational study design cannot establish causality for prognostic factors.

Provenance

Source

Dryad, authored by Annie Lannuzel.

Collection Method

Observational study of consecutive ZIKV-infected patients presenting with neurological manifestations.

Time Range

2016 outbreak period.

Freshness

Data reflects the 2016 outbreak, with the dataset last updated in 2020.

Geography

French West Indies.